A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma.
Preclinical studies in mice have demonstrated that the prophylactic depletion of immunosuppressive regulatory T-cells (T(Regs)) through targeting the high affinity interleukin-2 (IL-2) receptor (IL-2Rα/CD25) can enhance anti-tumor immunotherapy. However, therapeutic approaches are complicated by the...
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3288003?pdf=render |
id |
doaj-9c5a1bf348704ed5af50908203b99a21 |
---|---|
record_format |
Article |
spelling |
doaj-9c5a1bf348704ed5af50908203b99a212020-11-25T01:01:39ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0172e3104610.1371/journal.pone.0031046A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma.John H SampsonRobert J SchmittlingGary E ArcherKendra L CongdonSmita K NairElizabeth A ReapAnnick DesjardinsAllan H FriedmanHenry S FriedmanJames E HerndonApril CoanRoger E McLendonDavid A ReardonJames J VredenburghDarell D BignerDuane A MitchellPreclinical studies in mice have demonstrated that the prophylactic depletion of immunosuppressive regulatory T-cells (T(Regs)) through targeting the high affinity interleukin-2 (IL-2) receptor (IL-2Rα/CD25) can enhance anti-tumor immunotherapy. However, therapeutic approaches are complicated by the inadvertent inhibition of IL-2Rα expressing anti-tumor effector T-cells.To determine if changes in the cytokine milieu during lymphopenia may engender differential signaling requirements that would enable unarmed anti-IL-2Rα monoclonal antibody (MAbs) to selectively deplete T(Regs) while permitting vaccine-stimulated immune responses.A randomized placebo-controlled pilot study was undertaken to examine the ability of the anti-IL-2Rα MAb daclizumab, given at the time of epidermal growth factor receptor variant III (EGFRvIII) targeted peptide vaccination, to safely and selectively deplete T(Regs) in patients with glioblastoma (GBM) treated with lymphodepleting temozolomide (TMZ).Daclizumab treatment (n = 3) was well-tolerated with no symptoms of autoimmune toxicity and resulted in a significant reduction in the frequency of circulating CD4+Foxp3+ TRegs in comparison to saline controls (n = 3)( p = 0.0464). A significant (p<0.0001) inverse correlation between the frequency of TRegs and the level of EGFRvIII specific humoral responses suggests the depletion of TRegs may be linked to increased vaccine-stimulated humoral immunity. These data suggest this approach deserves further study.ClinicalTrials.gov NCT00626015.http://europepmc.org/articles/PMC3288003?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
John H Sampson Robert J Schmittling Gary E Archer Kendra L Congdon Smita K Nair Elizabeth A Reap Annick Desjardins Allan H Friedman Henry S Friedman James E Herndon April Coan Roger E McLendon David A Reardon James J Vredenburgh Darell D Bigner Duane A Mitchell |
spellingShingle |
John H Sampson Robert J Schmittling Gary E Archer Kendra L Congdon Smita K Nair Elizabeth A Reap Annick Desjardins Allan H Friedman Henry S Friedman James E Herndon April Coan Roger E McLendon David A Reardon James J Vredenburgh Darell D Bigner Duane A Mitchell A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma. PLoS ONE |
author_facet |
John H Sampson Robert J Schmittling Gary E Archer Kendra L Congdon Smita K Nair Elizabeth A Reap Annick Desjardins Allan H Friedman Henry S Friedman James E Herndon April Coan Roger E McLendon David A Reardon James J Vredenburgh Darell D Bigner Duane A Mitchell |
author_sort |
John H Sampson |
title |
A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma. |
title_short |
A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma. |
title_full |
A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma. |
title_fullStr |
A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma. |
title_full_unstemmed |
A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma. |
title_sort |
pilot study of il-2rα blockade during lymphopenia depletes regulatory t-cells and correlates with enhanced immunity in patients with glioblastoma. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2012-01-01 |
description |
Preclinical studies in mice have demonstrated that the prophylactic depletion of immunosuppressive regulatory T-cells (T(Regs)) through targeting the high affinity interleukin-2 (IL-2) receptor (IL-2Rα/CD25) can enhance anti-tumor immunotherapy. However, therapeutic approaches are complicated by the inadvertent inhibition of IL-2Rα expressing anti-tumor effector T-cells.To determine if changes in the cytokine milieu during lymphopenia may engender differential signaling requirements that would enable unarmed anti-IL-2Rα monoclonal antibody (MAbs) to selectively deplete T(Regs) while permitting vaccine-stimulated immune responses.A randomized placebo-controlled pilot study was undertaken to examine the ability of the anti-IL-2Rα MAb daclizumab, given at the time of epidermal growth factor receptor variant III (EGFRvIII) targeted peptide vaccination, to safely and selectively deplete T(Regs) in patients with glioblastoma (GBM) treated with lymphodepleting temozolomide (TMZ).Daclizumab treatment (n = 3) was well-tolerated with no symptoms of autoimmune toxicity and resulted in a significant reduction in the frequency of circulating CD4+Foxp3+ TRegs in comparison to saline controls (n = 3)( p = 0.0464). A significant (p<0.0001) inverse correlation between the frequency of TRegs and the level of EGFRvIII specific humoral responses suggests the depletion of TRegs may be linked to increased vaccine-stimulated humoral immunity. These data suggest this approach deserves further study.ClinicalTrials.gov NCT00626015. |
url |
http://europepmc.org/articles/PMC3288003?pdf=render |
work_keys_str_mv |
AT johnhsampson apilotstudyofil2rablockadeduringlymphopeniadepletesregulatorytcellsandcorrelateswithenhancedimmunityinpatientswithglioblastoma AT robertjschmittling apilotstudyofil2rablockadeduringlymphopeniadepletesregulatorytcellsandcorrelateswithenhancedimmunityinpatientswithglioblastoma AT garyearcher apilotstudyofil2rablockadeduringlymphopeniadepletesregulatorytcellsandcorrelateswithenhancedimmunityinpatientswithglioblastoma AT kendralcongdon apilotstudyofil2rablockadeduringlymphopeniadepletesregulatorytcellsandcorrelateswithenhancedimmunityinpatientswithglioblastoma AT smitaknair apilotstudyofil2rablockadeduringlymphopeniadepletesregulatorytcellsandcorrelateswithenhancedimmunityinpatientswithglioblastoma AT elizabethareap apilotstudyofil2rablockadeduringlymphopeniadepletesregulatorytcellsandcorrelateswithenhancedimmunityinpatientswithglioblastoma AT annickdesjardins apilotstudyofil2rablockadeduringlymphopeniadepletesregulatorytcellsandcorrelateswithenhancedimmunityinpatientswithglioblastoma AT allanhfriedman apilotstudyofil2rablockadeduringlymphopeniadepletesregulatorytcellsandcorrelateswithenhancedimmunityinpatientswithglioblastoma AT henrysfriedman apilotstudyofil2rablockadeduringlymphopeniadepletesregulatorytcellsandcorrelateswithenhancedimmunityinpatientswithglioblastoma AT jameseherndon apilotstudyofil2rablockadeduringlymphopeniadepletesregulatorytcellsandcorrelateswithenhancedimmunityinpatientswithglioblastoma AT aprilcoan apilotstudyofil2rablockadeduringlymphopeniadepletesregulatorytcellsandcorrelateswithenhancedimmunityinpatientswithglioblastoma AT rogeremclendon apilotstudyofil2rablockadeduringlymphopeniadepletesregulatorytcellsandcorrelateswithenhancedimmunityinpatientswithglioblastoma AT davidareardon apilotstudyofil2rablockadeduringlymphopeniadepletesregulatorytcellsandcorrelateswithenhancedimmunityinpatientswithglioblastoma AT jamesjvredenburgh apilotstudyofil2rablockadeduringlymphopeniadepletesregulatorytcellsandcorrelateswithenhancedimmunityinpatientswithglioblastoma AT darelldbigner apilotstudyofil2rablockadeduringlymphopeniadepletesregulatorytcellsandcorrelateswithenhancedimmunityinpatientswithglioblastoma AT duaneamitchell apilotstudyofil2rablockadeduringlymphopeniadepletesregulatorytcellsandcorrelateswithenhancedimmunityinpatientswithglioblastoma AT johnhsampson pilotstudyofil2rablockadeduringlymphopeniadepletesregulatorytcellsandcorrelateswithenhancedimmunityinpatientswithglioblastoma AT robertjschmittling pilotstudyofil2rablockadeduringlymphopeniadepletesregulatorytcellsandcorrelateswithenhancedimmunityinpatientswithglioblastoma AT garyearcher pilotstudyofil2rablockadeduringlymphopeniadepletesregulatorytcellsandcorrelateswithenhancedimmunityinpatientswithglioblastoma AT kendralcongdon pilotstudyofil2rablockadeduringlymphopeniadepletesregulatorytcellsandcorrelateswithenhancedimmunityinpatientswithglioblastoma AT smitaknair pilotstudyofil2rablockadeduringlymphopeniadepletesregulatorytcellsandcorrelateswithenhancedimmunityinpatientswithglioblastoma AT elizabethareap pilotstudyofil2rablockadeduringlymphopeniadepletesregulatorytcellsandcorrelateswithenhancedimmunityinpatientswithglioblastoma AT annickdesjardins pilotstudyofil2rablockadeduringlymphopeniadepletesregulatorytcellsandcorrelateswithenhancedimmunityinpatientswithglioblastoma AT allanhfriedman pilotstudyofil2rablockadeduringlymphopeniadepletesregulatorytcellsandcorrelateswithenhancedimmunityinpatientswithglioblastoma AT henrysfriedman pilotstudyofil2rablockadeduringlymphopeniadepletesregulatorytcellsandcorrelateswithenhancedimmunityinpatientswithglioblastoma AT jameseherndon pilotstudyofil2rablockadeduringlymphopeniadepletesregulatorytcellsandcorrelateswithenhancedimmunityinpatientswithglioblastoma AT aprilcoan pilotstudyofil2rablockadeduringlymphopeniadepletesregulatorytcellsandcorrelateswithenhancedimmunityinpatientswithglioblastoma AT rogeremclendon pilotstudyofil2rablockadeduringlymphopeniadepletesregulatorytcellsandcorrelateswithenhancedimmunityinpatientswithglioblastoma AT davidareardon pilotstudyofil2rablockadeduringlymphopeniadepletesregulatorytcellsandcorrelateswithenhancedimmunityinpatientswithglioblastoma AT jamesjvredenburgh pilotstudyofil2rablockadeduringlymphopeniadepletesregulatorytcellsandcorrelateswithenhancedimmunityinpatientswithglioblastoma AT darelldbigner pilotstudyofil2rablockadeduringlymphopeniadepletesregulatorytcellsandcorrelateswithenhancedimmunityinpatientswithglioblastoma AT duaneamitchell pilotstudyofil2rablockadeduringlymphopeniadepletesregulatorytcellsandcorrelateswithenhancedimmunityinpatientswithglioblastoma |
_version_ |
1725208017688854528 |